Anti-inflammatory Therapy for Recurrent In-stent Restenosis

Inclusion Criteria: 1. CAD patients over 18 years old; 2. At least one coronary artery lesion meets the RISR criteria: target lesion ≥ 2 ISRs (stenosis of lumen diameter within the stent segment and within 5mm near and far of the stent ≥ 50%); 3. Intended intervention treatment for RISR lesions; 4. Acceptable for standard secondary prevention drug therapy for coronary heart disease, including dual antiplatelet therapy (DAPT) and statins; 5. Willing to participate in the trial and complete follow-up, signing an informed consent form approved by the ethics committee Exclusion Criteria: 1. The previous interventional treatment situation is unknown; 2. The mechanism of intracavitary imaging to clarify ISR is operator-related (poor stent adhesion, incomplete dilation, and stent fracture); 3. Clearly diagnose vascular inflammatory diseases or connective tissue diseases (including arteritis, Behcet's disease, systemic lupus erythematosus, etc.) involving the coronary artery; 4. Immunosuppressive drugs, including glucocorticoids, have been used in the past 30 days; 5. There are contraindications to the use of prednisone or colchicine, including: serious infectious diseases, including active infection, hepatitis B, hepatitis C or AIDS patients; Hematological diseases, such as thrombocytopenia, severe anemia, leukemia, etc; Uncontrolled diabetes; Severe liver and kidney function damage; Active peptic ulcer or gastrointestinal bleeding; Severe osteoporosis (with previous pathological fractures); Inflammatory bowel disease or chronic diarrhea; 6. A history of malignant tumors within 3 years; 7. Cognitive impairment; 8. Not willing to participate or follow up